Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 2Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Pain, Postoperative 1Oropharyngeal Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Hodgkin Disease 1Carcinoma, Small Cell 1Anus Neoplasms 1

Interventions

Etoposide 18Carboplatin 18pembrolizumab 15Nivolumab 11Cisplatin 11atezolizumab 8Topotecan 8Irinotecan 7Temozolomide 6Paclitaxel 5PM 01183 5Ipilimumab 5Gemcitabine 5olaparib 4Radiotherapy 4Docetaxel 4surufatinib 3durvalumab 3carfilzomib 3Bevacizumab 3veliparib 2trilaciclib 2sacituzumab govitecan 2rovalpituzumab tesirine 2obatoclax 2niraparib 2navitoclax 2lorvotuzumab mertansine 2lenvatinib 2fluzoparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Small Cell Lung Carcinoma × Epinephrine × Clear all
NCT03554473 2025-05-09

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
37 enrolled 19 charts
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡